Mana.bio closes oversubscribed $19.5M seed funding

Mana.bio Advances AI-Based Lipid Nanoparticle (LNP) Platform to Accelerate “Programmable Drug Delivery” for RNA and Gene Therapies

– Mana.bio’s first-of-its-kind AI platform discovers and optimizes novel, customizable LNPs for tissue-specific delivery of nucleic acid-based therapeutics and vaccines

– Led by a multidisciplinary team with expertise in drug delivery, nanotechnology, and machine learning, Mana.bio closes oversubscribed $19.5M seed funding from Andreessen Horowitz Bio + Health, Base4 Capital, NFX, LionBird, and Technion Institute of Technology

Read the full announcement here